These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 26540259)

  • 21. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
    Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
    Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
    Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
    Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
    Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
    Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
    Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
    Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
    Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.
    Fassnacht-Riederle H; Becker M; Graf N; Michels S
    Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1705-9. PubMed ID: 24614949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration.
    Aldhanhani AA; Azzam OA; AlAli SH; Almasri KG; Aljneibi SH; Pichi F
    Int Ophthalmol; 2024 Sep; 44(1):369. PubMed ID: 39235669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION.
    Matsumoto H; Sato T; Morimoto M; Mukai R; Takahashi M; Hiroe T; Ehara K; Takayama M; Mimura K; Kishi S
    Retina; 2016 Dec; 36(12):2282-2289. PubMed ID: 27336229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.